PTX prescient therapeutics limited

Ann: September 2023 Quarterly Update and Appendix 4C, page-23

  1. 464 Posts.
    lightbulb Created with Sketch. 131

    If the stars align we could see ourselves in an envious position. Come Q1 2024 we could be approved for a registration study for PTX-100. Hopefully by then, the market has changed its sentiment towards the biotech sector.I found this post on LinkedIn interesting from our very own Dan Shelly. FYI BioEurope is the Industries largest networking event. Pretty much speed dating for biotech companies!
    https://hotcopper.com.au/data/attachments/5702/5702076-051757707ed8110cb67365ee4e108d84.jpg
    I would suggest it seems that Steven is hoping to leverage the success of PTX-100 to raise capital to help fund our Omnicar trials. With a bit of luck we could also see one or more partnerships for Cellpryme. He isn’t going to just let his Ferrari sit in the garage is he?
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
4.7¢
Change
0.000(0.00%)
Mkt cap ! $37.85M
Open High Low Value Volume
4.7¢ 4.9¢ 4.4¢ $171.3K 3.640M

Buyers (Bids)

No. Vol. Price($)
1 150000 4.8¢
 

Sellers (Offers)

Price($) Vol. No.
4.9¢ 486590 4
View Market Depth
Last trade - 15.56pm 18/07/2025 (20 minute delay) ?
PTX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.